Fatty Liver Disease Treatment in Nagpur

Fatty Liver Disease Types and Classification

NAFLD (Non-Alcoholic Fatty Liver Disease – 25-30% Population)

NAFLD occurs in patients without significant alcohol consumption and affects 25-30% globally. The condition is strongly associated with obesity, metabolic syndrome, and type 2 diabetes. NAFLD ranges from simple steatosis (NAFL) without inflammation to NASH with fibrosis. NAFLD treatment in Nagpur addresses metabolic dysfunction preventing progression.

AFLD (Alcoholic Fatty Liver Disease)

AFLD develops from chronic heavy alcohol consumption exceeding 2 drinks daily (women) or 3 drinks daily (men). Alcohol metabolism generates excessive acetyl-CoA promoting hepatic triglyceride synthesis. AFLD progresses from simple steatosis to alcoholic hepatitis and cirrhosis. Complete alcohol abstinence is mandatory for AFLD treatment and recovery.

Fatty Liver Disease Symptoms

• Fatigue and low energy levels

• Right upper quadrant abdominal discomfort

• Hepatomegaly (enlarged liver) on physical exam

• Abdominal bloating and distension

• Unexplained weight loss in advanced cases

• Jaundice (yellowing of skin/eyes) if cirrhosis develops

• Ascites (abdominal fluid) in cirrhotic patients

• Spider angiomas and palmar erythema

• Portal hypertension signs

• Hepatic encephalopathy (confusion) in severe cases

Most patients with fatty liver disease are asymptomatic with disease discovered incidentally on imaging. Symptoms typically develop only with advanced fibrosis or cirrhosis.

Fatty Liver Disease Causes and Risk Factors

Metabolic and Obesity Factors

• Obesity (BMI >25 kg/m²) affecting 80% of NAFLD patients

• Central/abdominal obesity with visceral fat accumulation

• Insulin resistance promoting hepatic triglyceride synthesis

• Type 2 diabetes increasing NAFLD prevalence to 50%

• Metabolic syndrome (3 of 5 criteria present)

Dietary Risk Factors

• High calorie intake exceeding energy expenditure

• Excessive refined carbohydrate consumption

• High-fructose corn syrup and added sugars

• Saturated fat consumption promoting liver fat

• Low dietary fiber intake

• Processed food consumption

Genetic and Familial Factors

• Family history of liver disease

• PNPLA3 genetic variant increasing fibrosis risk

• Increased genetic susceptibility

• Ethnic variations in disease prevalence

• Female sex associated with higher NASH risk

Alcohol Consumption (AFLD)

• Chronic alcohol use exceeding guidelines

• Acetaldehyde toxicity from alcohol metabolism

• Oxidative stress and mitochondrial damage

• Impaired antioxidant defenses

• Alcohol-induced inflammation

Other Contributing Factors

• Sleep apnea with intermittent hypoxia

• Hepatitis C coinfection accelerating disease

• Hepatitis B increasing NAFLD severity

• Medications (corticosteroids, antiretrovirals)

• Rapid weight loss mobilizing hepatic fat

Fatty Liver Disease Diagnosis

Clinical Assessment

• Symptom evaluation and patient history

• Obesity and metabolic disorder documentation

• Alcohol consumption quantification

• Family history evaluation

Laboratory Tests

• Liver function tests (AST, ALT, ALP, bilirubin)

• AST/ALT ratio assessment (>1 suggests cirrhosis)

• Platelet count and INR (synthetic function)

• Viral hepatitis serology (HBsAg, anti-HCV)

• Lipid panel and glucose levels

Non-Invasive Fibrosis Scoring

FIB-4 Index = (Age × AST) / (Platelet count × √ALT)

• FIB-4 <1.30: Low fibrosis risk (observation)

• FIB-4 1.30-2.67: Intermediate risk (fibroscan indicated)

• FIB-4 >2.67: High fibrosis risk (urgent treatment)

Imaging Studies

• Ultrasound: Hepatic steatosis with bright liver appearance

• CT scan: Decreased liver attenuation indicating fat

• MRI-PDFF: Quantifies steatosis percentage precisely

• Elastography: Assesses portal hypertension features

Transient Elastography (Fibroscan)

Fibroscan measures liver stiffness predicting fibrosis non-invasively:

• F0-F1 (<6.0 kPa): No/minimal fibrosis (safe observation)

• F2 (6.0-8.0 kPa): Significant fibrosis (treatment indicated)

• F3 (8.0-12.0 kPa): Advanced fibrosis (urgent intervention)

• F4 (>12.0 kPa): Cirrhosis (HCC screening initiated)

Fatty Liver Disease Treatment

Lifestyle Modifications (First-Line Therapy)

Weight Loss Program

• 5-10% weight loss improves steatosis significantly

• 10% weight loss improves inflammation and fibrosis

• Gradual weight loss (0.5 kg/week) is sustainable

• Combined diet and exercise most effective

Dietary Changes

• Mediterranean diet rich in olive oil and fish

• Low-FODMAP diet reduces bloating if IBS concurrent

• Fructose restriction limiting high-fructose corn syrup

• Adequate protein (25-30% calories) improves satiety

• Fat restriction (<50 grams daily) for optimal results

Physical Activity

• Aerobic exercise 150 minutes weekly

• Resistance training 2-3 times weekly

• Improves insulin sensitivity and hepatic fat

• Any exercise better than none; consistency matters

Alcohol Abstinence

• Mandatory complete cessation in AFLD

• Moderate restriction even in NAFLD

• Fibrosis can regress with sustained abstinence

• Smoking cessation improves cardiovascular outcomes

Pharmacological Treatment

Vitamin E Therapy

• 800 IU daily improves NASH histology in non-diabetic patients

• Reduces ALT, steatosis, and inflammatory activity

• Recommended for biopsy-proven NASH without diabetes

• Long-term safety concerns exist

Pioglitazone (Thiazolidinedione)

• 15-30 mg daily improves NASH histology

• Insulin sensitizer reducing hepatic fat accumulation

• Improves steatosis, inflammation, and fibrosis

• Weight gain and fluid retention limit use

• Viable for insulin-resistant patients

Bariatric Surgery

• Achieves 30-50 kg average weight loss

• NASH resolution occurs in 90% post-operatively

• Reverses hepatic inflammation and fibrosis

• Reserved for BMI >40 or >35 with comorbidities

Fatty Liver Disease Complications

• Cirrhosis: Progressive fibrosis causing portal hypertension

• Hepatocellular carcinoma (HCC): 2-5% annual incidence in cirrhosis

• Portal hypertension: Esophageal varices, ascites

• Hepatic encephalopathy: Confusion and altered consciousness

• Liver failure: Coagulopathy, hyperbilirubinemia

• Variceal bleeding: Life-threatening hemorrhage

• Ascites: Abdominal fluid accumulation

• Infections: Spontaneous bacterial peritonitis

Fatty Liver Disease Prevention and Management

• Weight loss: Achieve and maintain healthy BMI

• Dietary modification: Avoid high-calorie, high-sugar foods

• Regular exercise: 150 minutes aerobic weekly

• Alcohol abstinence: Complete cessation in AFLD

• Diabetes control: Maintain HbA1c <7%

• Smoking cessation: Reduces disease progression

• Regular monitoring: Annual fibroscan if advanced fibrosis

• HCC screening: 6-monthly ultrasound if cirrhosis present